GSK is taking to the airwaves to get the message out about respiratory syncytial virus (RSV), presenting a TV special about how the pathogen has affected athletes in the upcoming National Senior Games ...

London: GSK plc has announced that the US Food and Drug Administration (FDA) has accepted for review an application to extend the indication of Arexvy (respiratory syncytial virus (RSV) ...

British drugmaker GSK said on Monday it had submitted an application to the U.S. Food and Drug Administration to extend the ...

GSK sponsors the 2025 National Senior Games to raise awareness about RSV risks and prevention for older adults through education and athlete stories.

A single dose of RSVPreF3 OA offered protection against RSV-related lower respiratory tract disease across three RSV seasons ...

"GSK’s speciality medicines soar while generals drop, Q2 results reveal " was originally created and published by ...

GSK Plc reported better-than-expected profit and raised its estimates for revenue at two key divisions in a report that ...

Zinger Key Points FDA to decide by H1 2026 on expanding GSK's RSV vaccine to at-risk adults aged 18–49. 21 million U.S. adults under 50 have conditions putting them at risk for severe RSV.

GSK CEO Emma Walmsley's bet on Arexvy has hit a snag in recent months after the U.S. public health agency narrowed the age recommendation for use of RSV vaccines and delayed the recommendation for ...

The Food and Drug Administration on Wednesday approved the world’s first RSV vaccine: a shot for adults ages 60 and up, made by pharmaceutical giant GSK. The milestone was decades in the making.